ANNOUNCING CANN GROUP AS A SILVER PARTNER OF CANNABIS OCEANIA AND CANNABIS EUROPA
Established in 2014, Cann Group Limited is an Australian-based leader in medicinal cannabis with a focus on local cultivation and manufacture of products designed to meet the needs of medical patients in Australia and around the world.
Cann Group was the first company to be issued with both the Cannabis Research Licence and Medicinal Cannabis Licences by the Australian Government’s Office of Drug Control (ODC) allowing for the cultivation and production of cannabis. Cann Group has built up its production capability to now being able to provide a full range of Good Manufacturing Practice (GMP) compliant cannabis products for Australian patients and for export around the world.
“Cann Group has existing offtake and supply agreements with partners in Australia, North America and Europe, to supply commercial, innovative finished-product formulations to GMP standards.” — Shane Duncan, COO of Cann Group Limited.
Through ongoing research and drawing on the experience of medical practitioners and patients, Cann Group aims to continue to expand the firm’s available product pipeline of unique medical products designed to address specific needs and improve peoples’ quality of life.
“Cultivating since 2017, Cann Group operates from two existing production facilities in Melbourne and has commenced construction on a large-scale, state-of-the-art production and manufacturing facility in regional Victoria.” — Peter Crock, CEO of Cann Group Limited.
Cann Group will be joining Prohibition Partners LIVE to share insights accumulated over years of experience in cultivating and manufacturing medicinal cannabis products for the Australian and overseas patient communities.
Join Prohibition Partners LIVE on 22 – 23 June to discover the latest developments in the European cannabis sector, learn from our world-renowned speakers, and engage with our network of industry-leading professionals who are pushing boundaries in the cannabis space.